There’s a patient profile I see repeatedly across my addiction psychiatry panel: mid-forties, carries significant weight, drinking heavily, and has already cycled through naltrexone without meaningful response. They’re not treatment-resistant in the traditional sense — they’re medication-undertreated in a field where the approved pharmacotherapy menu has barely moved in thirty years. When the Lancet published its randomized, double-blind, placebo-controlled trial of once-weekly semaglutide in patients with alcohol use disorder and comorbid obesity this week, I read it as a direct clinical signal, not an academic curiosity.
The trial showed robust therapeutic effects on alcohol use in treatment-seeking participants. That phrase — treatment-seeking — matters enormously. These are patients with the motivation and the metabolic profile that sponsors spend years trying to enroll. And semaglutide delivered signal in both directions simultaneously: body weight and drinking behavior.
Why the Dual Phenotype Is the Story
The assumption most sponsors carry into SUD trial design is that obesity is a confounder to control for, not a therapeutic lever to pull. That logic deserves scrutiny. A research letter published in JAMA Internal Medicine on April 28, 2026, found that nearly 1 in 10 U.S. adults in 2023 had both heavy alcohol use and obesity — a comorbidity pairing that dramatically elevates liver disease risk. Designing a trial that treats these as separate problems misses the shared neurobiology underneath them.
GLP-1 receptors are expressed in the mesolimbic reward circuitry — the ventral tegmental area, nucleus accumbens, prefrontal cortex. The same pathway that mediates caloric reward modulates alcohol craving. When semaglutide attenuates reward salience for food, the attenuation doesn’t stop at the refrigerator door.
The population-level evidence is accumulating fast. A study published in The BMJ on March 4, 2026, by Washington University School of Medicine analyzed electronic health records from 606,434 U.S. veterans with type 2 diabetes and found GLP-1 receptor agonists associated with reduced risk of developing various substance use disorders and decreased severe harm in those already affected. That’s an observational signal across more than half a million patients. The Lancet trial now provides the randomized confirmation that the mechanism is real and clinically meaningful in AUD specifically.
Prior clinical evidence was already pointing here. A phase 2 trial in 48 non-treatment-seeking adults with AUD — 71% female, mean age 39.9 — showed semaglutide reducing alcohol consumption and craving in a controlled setting. The Lancet trial extends that signal into treatment-seeking patients with obesity, a population where the stakes and the enrollment feasibility are both substantially higher.
The Medication Gap Sponsors Keep Underestimating
Oral naltrexone has been FDA-approved for alcohol dependence since 1994. Injectable naltrexone (Vivitrol) received approval in 2006. Acamprosate followed. Disulfiram predates all of them. And across all of these options, fewer than 2% of patients with AUD in the United States receive any pharmacotherapy.
That number should stop every sponsor in this space cold.
The uptake failure reflects real-world complexity that clinical protocols systematically underweight: stigma, prescriber reluctance, insurance barriers, and the simple fact that many patients with AUD carry comorbid depression, anxiety, or other SUD — conditions that existing agents weren’t designed to address simultaneously. A once-weekly subcutaneous injection that a patient is already familiar with from obesity treatment, carrying an established FDA approval for chronic weight management since June 2021, sidesteps several of those friction points in ways that a new chemical entity simply cannot.
In my practice, the patients most likely to accept a pharmacotherapy for AUD are the ones who already have a therapeutic relationship with their prescriber built around something else — weight, diabetes, metabolic risk. Semaglutide enters through a door that’s already open.
What This Means for the Next Trial
The gastrointestinal tolerability profile — nausea, appetite suppression, vomiting reported in the Lancet cohort per AJMC’s reporting — will require careful protocol management in a population that may also be experiencing alcohol withdrawal-related GI symptoms at baseline. Distinguishing drug-related from withdrawal-related adverse events is an endpoint design problem that a sponsor without addiction psychiatry experience will underestimate. Washout timing, baseline symptom capture, and withdrawal severity stratification need to be built into the protocol architecture from day one, not addressed in an amendment.
The dual-indication trial design this data supports — AUD and obesity as co-primary indications — is also operationally demanding in ways that single-indication metabolic trials are not. Retention in AUD populations runs lower than in obesity trials unless the site has an established therapeutic relationship with the population. Across my patient panel, retention in structured programs with psychiatric support runs well above industry benchmarks — because the patients aren’t just enrolled, they’re held.
Novo Nordisk holds the semaglutide franchise and already carries the cardiovascular outcomes data from SELECT, the obesity approval, and the diabetes label. An AUD indication would extend semaglutide’s reach into a therapeutic area where no branded agent has achieved meaningful market penetration — and where a once-weekly injection with an existing safety database carries a commercial argument that thirty years of oral naltrexone data could not.
The next signal to watch: whether Novo Nordisk files for a formal AUD indication or whether the data creates an opening for a GLP-1 competitor to build a purpose-designed addiction psychiatry program. Either way, the mechanism is validated. The enrollment population exists. The question sponsors are about to start asking is which sites have them.
References
- The Lancet — “Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial”
- PubMed — Phase 2 trial of semaglutide in non-treatment-seeking adults with alcohol use disorder (48 participants)
- NCBI Bookshelf — FDA approval history of naltrexone for alcohol dependence
- Healio — “FDA approves once-weekly semaglutide for weight loss,” June 4, 2021
- Medical Dialogues — JAMA Internal Medicine study on heavy alcohol use and obesity comorbidity, April 28, 2026
- Washington University School of Medicine — BMJ study: GLP-1 agonists and substance use disorder risk in 606,434 veterans, March 4, 2026
- AJMC — “GLP-1s Reduce Heavy Drinking Days in Patients With Obesity, Alcohol Use Disorder”
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
